A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ACC, AHA Issue Aortic Disease Guideline

New guidance covers recommendations for surgical intervention, consistent imaging techniques, family screening, and the importance of a multidisciplinary team

The American College of Cardiology and the American Heart Association have published a new guideline on the diagnosis and management of aortic disease, focusing on surgical intervention considerations, consistent imaging practices, genetic and familial screenings, and the importance of a multidisciplinary aortic team.

The aorta is the largest artery in the body and carries oxygen-rich blood from the heart to the rest of the body. Aortic disease occurs when the aortic wall is weakened and either bulges, causing an aortic aneurysm or tears, causing an aortic dissection. A ruptured aneurysm or severe dissection may be immediately fatal. If either is discovered via imaging tests, lifesaving treatment can include careful monitoring the injured aorta, surgery, medication and/or lifestyle changes. Symptoms of aortic disease include chest pain or pressure, back pain, fatigue, neck pain or jaw pain.

“There has been a host of new evidence-based research available for clinicians in the past decade when it comes to aortic disease. It was time to re-evaluate and update the previous, existing guidelines,” said Eric M. Isselbacher, MD, MSc, guideline writing committee chair. “We hope this new guideline can inform clinical practices with up-to-date and synthesized recommendations, targeted toward a full multidisciplinary aortic team working to provide the best possible care for this vulnerable patient population.”

Recommendations in the new guideline include:

Family screening – To identify individuals most at risk for aortic disease, the new guideline recommends family screening, including genetic testing and imaging, of first-degree relatives of individuals diagnosed with aneurysms of the aortic root or ascending thoracic aorta, or those with aortic dissection.

Consistency in imaging – The guideline stresses the importance of consistency in the way CT or MRI imaging is obtained and reported, in the measurement of aortic size and features, and in how often images are used for monitoring before and after repair surgery or other intervention. Ideally, all surveillance imaging for a patient should be done using the same modality and in the same lab.

Patient size adjustments – The guideline recommends modifying surgical thresholds in patients who are significantly smaller or taller than average. Guidance for the size of aortic injury that would indicate a need for surgery should be adjusted for the patient’s body surface area or height.

Surgery – At institutions with multidisciplinary aortic teams and experienced surgeons, the threshold for surgical intervention for sporadic aortic root and ascending aortic aneurysms has been lowered from 5.5 cm to 5.0 cm in certain individuals. Risk of aortic aneurysm or dissection increases with size. With this recommendation, select individuals may get lifesaving surgery sooner to prevent death from an aortic aneurysm or dissection. In addition, the guideline updates the definition for rapid aneurysm growth rate: surgery is recommended for individuals with aneurysms of aortic root and ascending thoracic aorta with a confirmed growth rate of ≥0.3 cm per year across two consecutive years or ≥0.5 cm in one year. Rapid aortic growth is a risk factor for rupture.

Multidisciplinary aortic teams – For individuals who require aortic intervention, outcomes are optimized when surgery is performed by an experienced surgeon working in a multidisciplinary aortic team. The new guideline recommends “a specialized hospital team with expertise in the evaluation and management of aortic disease, in which care is delivered in a comprehensive, multidisciplinary manner.” These teams may consist of cardiac and vascular surgeons with extensive experience managing complex aortic disease at a center with a high volume of aortic interventions; imaging specialists with expertise in aortic disease who can interpret CT, MRI and echocardiography; anesthesiologists experienced in the management of acute aortic disease and cerebrospinal fluid drainage; and an intensive care unit experienced in the management of acute aortic disease.

Shared decision-making – The multidisciplinary aortic team is highly encouraged to involve the patient in decision-making, especially when individuals are on the borderline of thresholds for repair or eligible for different types of surgical repair. Shared decision-making should also be used with individuals who are pregnant or may become pregnant to consider the risks of pregnancy in individuals with aortic disease. Shared decision-making has become increasingly important in patient-centered care and may be especially useful when discussing quality of life, goals of care and desired procedural outcomes.

This new aortic disease guideline replaces the “2010 ACCF/AHA Guidelines for the Diagnosis and Management of Patients with Thoracic Aortic Disease” and the “2015 Surgery for Aortic Dilation in Patients with Bicuspid Aortic Valves: A Statement of Clarification from the ACC/AHA Task Force on Clinical Practice Guidelines.” It is intended to be used concurrently with the “2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease.” The new guideline brings together guidelines for both the thoracic and abdominal aorta and is targeted to cardiovascular clinicians who are involved in the care of people with aortic disease, including general cardiovascular care clinicians and emergency medicine clinicians.

The “2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease” will be published simultaneously in the Journal of the American College of Cardiology and the American Heart Association’s journal Circulation. The guideline was developed in collaboration with and endorsed by the American Association for Thoracic Surgery, the American College of Radiology, the Society of Cardiovascular Anesthesiologists, the Society for Cardiovascular Angiography and Interventions, the Society of Thoracic Surgeons, and the Society for Vascular Medicine. It was endorsed by the Society of Interventional Radiology and the Society of Vascular Surgery.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
To further understand the impact of platforms like TikTok on nutrition trends, MyFitnessPal partnered with Dublin City University on a research and experimental study that examined diet and nutrition content on TikTok. The study analyzed over 67,000 videos using Artificial Intelligence to compare them against public health and nutrition guidelines
Leveraging the power of Apple Vision Pro to seamlessly blend digital content with the physical world Osso Health brings the operating experience to life via detailed, clinically accurate workflows of common procedures.
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
The partnership is with Health-HavenRx ™, an online pharmacy platform. This partnership enables a new, convenient channel for patients to access POGO Automatic by using their health insurance on Intuity Medical’s e-commerce website at www.GoodtoPogo.com.

By using this website you agree to accept Medical Device News Magazine Privacy Policy